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Loa loa: More [36_TD$DIFF] han Meets the Eye?
Filarial nematodescauseneglected
tropical diseases (NTDs) such as
river blindness, elephantiasis, and
African eye worm. Global control
and elimination efforts are well
underway for the former two, and
epidemiological models have
played a crucial role in understand-
ing the impact of interventions and
guidingcontrol policy.However, for
the latter (caused by Loa loa), there
are no specific transmission mod-
els, and the disease has not been
included among the prioritized
NTDs. María-Gloria Basáñez and
her Helminth Ecology Research
Group at Imperial College [37_TD$DIFF]London
work collaboratively on developing
mathematical models for human
and zoonotic helminthiases and
other vector-borne NTDs. In this
interview, the authors shared with
Trends in Parasitology why loiasis
may be more than meets the eye
and howmodelling can best be lev-
eragedtohelpcontrolhumanfilarial
infections.
What does your research focus on? Is there an interesting story
behind why you chose this topic?
[38_TD$DIFF]Our research is primarily concerned with modelling the transmission dynamics of the
so-called NTDs, particularly (but not exclusively) those tackled by preventive chemo-
therapy, including filarial diseases. Caused by parasitic worms, these diseases include
onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) and they blight
the lives ofmillions of peopleworldwide. Themodels we develop capture the population
biology and epidemiological features of these parasites and are used to simulate and
evaluate the impact of interventions to support policy-makers in reaching their control
and elimination targets. Most of the interventions are presently based on treatment of
the affected human populations with antifilarial drugs distributed through mass drug
administration (i.e., without the need of an individual diagnosis of infection).
We are currently particularly interested in loiasis, a disease caused by another filarial
parasite, Loa loa. Loiasis (African eye worm) is typically considered to be benign, and
hence it has neither been included in the World Health Organization’s list of prioritized
NTDs nor considered in the Global Burden of Disease (GBD) studies. However, in
addition to causing relatively minor ocular and systemic symptoms in a large propor-
tion of those infected, new research has revealed a significant association between
high levels of infection and increased human mortality, indicating a hitherto unrec-
ognised public health importance. We want to understand better the population
biology and epidemiology of this somewhat mysterious and forgotten disease so
that we can develop new mathematical transmission models to inform the design of
intervention strategies.
What is the current status of loiasis?
Loiasis isendemicacrossabroadregionofcentralAfrica,hometoover30millionpeople,
with over 10million people thought to be infected, although this value is rather uncertain
and probably underestimated. No interventions currently target loiasis per se, although
manycommunitiesco[39_TD$DIFF]-endemicwithonchocerciasisand/or lymphaticfilariasisareserved
by annual or semi[40_TD$DIFF]-annual mass drug administration with ivermectin (for onchocerciasis)
and ivermectin plus albendazole for lymphatic filariasis. Loiasis has represented an
impediment to effective implementation of mass drug administration because of rare
but potentially severe adverse events following treatment with ivermectin in people with
heavy L. loa microfilarial infections. The microfilariae are the stages transmitted to the
insect vectors of these diseases, and hence, community-wide distribution of micro-
filaricidal drugs reduces transmission. However, in the case of loiasis, reactions to dead
microfilariae can cause disabling and even fatal encephalopathy. Hence, although
ivermectin is an efficacious treatment for loiasis, it is unsafe for people with heavy L.
loa infections, and for these people treatment options are more limited.
Are there any pressing steps that, in your opinion, should be taken
to control [41_TD$DIFF]loiasis?
The latest research findings indicate that loiasis is a disease of public health impor-
tance associated with significant excess mortality of heavily infected individuals.
Treatment options in these individuals are limited because of the risk of severe adverse
events following administration of otherwise efficacious microfilaricidal drugs.
Microfilaria of Loa loa. Credit: C.D. Mackenzie.
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Moreover, because loiasis has not previously been considered a public health concern
per se, the disease remains completely uncontrolled (and its prevalence can very high)
in communities where neither onchocerciasis nor lymphatic filariasis are co [39_TD$DIFF]-endemic.
We believe that steps should be taken to control loiasis in these communities via safe
delivery mechanisms, such as excluding heavily infected individuals from treatment,
but also by investigating the safety and efficacy of new or existing treatments (such as
albendazole) in heavily infected people. Methods for controlling the tabanid (horsefly)
vectors that transmit L. loa should also be urgently developed to complement these
chemotherapeutic strategies.
How can modelling best be leveraged to help control vector-borne
diseases?
The transmission dynamics of vector-borne diseases such as loiasis are underpinned
by interactions between populations of vectors, hosts, and parasites. Unlike oncho-
cerciasis and lymphatic filariasis, for which experimental infections of the insect vector
have been conducted to understand and quantify the processes determining vector
competence, loiasis still presents the exciting challenge of making more translucent
what has been a population biology black box. Such systems are characterised by
nonlinear and sometimes unintuitive dynamics during interventions. These features
limit the utility of formulating intervention strategies in an informal manner, without
explicit consideration of the underlying transmission dynamics and population pro-
cesses. Modelling incorporates these fundamental mechanistic processes and per-
mits prediction of otherwise elusive epidemiological trends under different postulated
intervention strategies. This provides a means to guide the design of interventions
targeting these diseases in terms of their likely effectiveness and cost-effectiveness in
attaining control and elimination goals.
What is the key message our readers should retain from your
review?
Despite the long-standing perception as a benign disease, and the paucity of recent
research, loiasis is a significant public health concern for millions of people living in
impoverished rural communities of central Africa and warrants more attention and
recognition by the global health community. Prerequisite to better control of loiasis is
better understanding of the population and transmission processes that shape the
epidemiology of this most neglected tropical disease. Ultimately, a better understand-
ing of these underlying processes will permit the design and implementation of
effective intervention strategies that will improve the health and wellbeing of millions
of affected people in the central regions of Africa.
Charles Whittaker,1 Martin Walker,1,2 Sébastien D.S. Pion,3 Cédric B. Chesnais,3
Michel Boussinesq,3 and María-Gloria Basáñez1,*
1Department of Infectious Disease Epidemiology, London Centre for Neglected Trop-
ical Disease Research and MRC Centre for Outbreak Analysis and Modelling, Faculty
of Medicine (St Mary’s Campus), Imperial College London, London W2 1PG, UK
2Department of Pathobiology and Population Sciences, London Centre for Neglected
Tropical Disease Research, Royal Veterinary College, Hawkshead Lane, Hatfield AL9
7TA, UK
262 Trends in Parasitology, April 2018, Vol. 34, No. 4
Spotlight
Praziquantel Interaction
with Mammalian
Targets in the Spotlight
Tim A. Day1,* and Michael
J. Kimber1
Chan et al. recently demonstrated
that the antischistosomal drug
praziquantel has a potent and spe-
cific interaction with human 5-
HT2B receptors, and that the drug
also elicits contraction of mouse
mesenteric vasculature apparently
mediated by the same receptor
subtype We consider what this
might mean about the drug’s
molecular therapeutic targets in
both the worm and the host.
Schistosomiasis continues to infect
between 230 and 440 million people
throughout the world [1]. Individual treat-
ment of the afflicted, programs to control
morbidity, andcampaigns forgeographical
eradication all depend heavily on chemo-
therapy in the persistent absence of effec-
tive vaccines. Praziquantel (PZQ) was
introduced in1978andhassince remained
the cornerstone of our antischistosomal
chemotherapeutic toolkit. Despite the
heavy reliance on PZQ to treat this devas-
tating disease, 40 years later, the drug’s
mechanism of action remains enigmatic.
PZQ has immediate, dramatic, and debil-
itating effects directly on schistosomes at
low concentrations (>1 mM). The most
obvious and immediate include a spastic
paralytic contraction of the somatic
musculature and a dramatic disruption
of the tegument, the worm's complex
outer surface. Widespread calcium dys-
regulation is tightly linked to these hall-
mark effects. The only molecular target in
the worm that has a demonstrated potent
and specific interaction with PZQ remains
an atypical schistosome b subunit of volt-
age-operated calcium channels (VOCCs)
[2]. PZQ (100 nM) enhances calcium cur-
rents through heterologously expressed
VOCCs containing these atypical subu-
nits. However, evidence of this interaction
actually occurring in worms continues to
escape detection, and there is compelling
evidence that these most obvious
responses are not sufficient to explain
PZQ’s therapeutic efficacy.
Chan et al. recently demonstrated that
PZQ binds to and acts as a partial agonist
at human 5-HT2B receptors at concen-
trations (10 mM) well within those
achieved in plasma through therapy [3].
This stereoselective effect was limited to
the (R) enantiomer, to which most of the
therapeutic efficacy is credited. In heter-
ologous expression assays, both recep-
tor binding and Ca2+ liberation occurred
below 10 mM. PZQ did not interact with
any other human 5-HT receptor subtypes
in similar concentration ranges.
The investigators also showed that (R)-
PZQ phenocopies serotonin-induced
contraction of the mesenteric vasculature
of mice; this effect on the mammalian
host requires concentrations significantly
higher than those needed to elicit
responses in worms, but still within those
achieved in the mesenteric blood flow
with therapeutic treatment (50 mM).
Further, the (R)-PZQ-induced constriction
of the murine mesenteric arteries was
blocked by the specific 5-HT2B receptor
antagonist SB204741, which also blocks
(R)-PZQ-induced Ca2+[29_TD$DIFF] liberation in cells
expressing human 5-HT2B receptors.
[30_TD$DIFF] oes this mean that PZQ could be
interactingwith a schistosomeG-pro-
tein-coupled receptor (GPCR) that is
like a mammalian 5-HT2B receptor?
[31_TD$DIFF] n the broadest sense, the work of Chan
et al. shows that PZQ interacts very spe-
cifically and stereoselectively with a
GPCR. At a minimum, these results sub-
stantively endorse the possibility that PZQ
could interact with a worm GPCR as part
of its therapeutic action.
It is worth noting that serotonin and PZQ
are both myoexcitatory on worms, but
their overall responses are significantly
different; there is not a serotonergic
response that mimics the overall PZQ
response. Further, schistosome recep-
tors readily recognizable as similar to
mammalian 5-HT2B receptors have not
yet been identified. That observation,
however, is only tenuously germane.
Most flatworm GPCRs remain classified
only by algorithmic forecast, and those
are quite unreliable at subtype level clas-
sification, especially when they are forced
to extrapolate backwards across vast
evolutionary distances. The lion’s share
of schistosome GPCRs remain
completely uncharacterized biologically.
It certainly remains possible that one of
the large number of uncharacterized
schistosome GPCRs could interact with
PZQ.
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